Get the Stockscreener App
11.10
2.38%
-0.26
After Hours:
11.18
0.08
+0.72%
Alumis Inc stock is traded at $11.10, with a volume of 3.08M.
It is down -2.38% in the last 24 hours and down -59.11% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
See More
Previous Close:
$11.36
Open:
$11.23
24h Volume:
3.08M
Relative Volume:
2.40
Market Cap:
$1.44B
Revenue:
$8.40M
Net Income/Loss:
$-237.42M
P/E Ratio:
-5.7773
EPS:
-1.9213
Net Cash Flow:
$-377.03M
1W Performance:
-50.45%
1M Performance:
-59.11%
6M Performance:
-61.59%
1Y Performance:
+141.09%
1-Day Range:
$11.01
$11.60
1-Week Range:
$8.75
$22.55
52-Week Range:
$3.76
$31.35
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
11.10 | 2.96B | 8.40M | -237.42M | -377.03M | -1.9213 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Initiated | Raymond James | Strong Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Jan-21-26 | Initiated | Chardan Capital Markets | Buy |
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
Alumis (NASDAQ:ALMS) Shares Down 7.9%What's Next? - MarketBeat
What Alumis (ALMS)'s Envudeucitinib Phase 3 Data and Deepening Losses Means For Shareholders - simplywall.st
Equities Analysts Set Expectations for Alumis Q3 Earnings - MarketBeat
H.C. Wainwright reiterates Alumis stock rating at neutral, $25 target - Investing.com
Venture investor’s big move: Latigo Biotherapeutics (ALMS) lands new 14.5% holder - Stock Titan
Alumis (NASDAQ:ALMS) Lowered to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Alumis' (ALMS) "Neutral" Rating Reaffirmed at HC Wainwright - MarketBeat
Alumis (NASDAQ:ALMS) Shares Gap Down After Earnings Miss - MarketBeat
ALMS Q1 2026 Earnings: Narrower-Than-Expected Loss Slightly Overshadows Share DeclineLong-Term Guidance - Vinanet
Alumis Swings to Q2 Net Loss, Revenue Falls - marketscreener.com
ALMS SWOT Analysis: Financial Challenges and Opportunities Revea - GuruFocus
Alumis (NASDAQ:ALMS) Issues Earnings Results - marketbeat.com
Alumis Q2 Results: EPS Misses Estimate, Sales Fall 37% YoY - scanx.trade
Alumis (ALMS) Posts Q2 Loss; Price-to-Sales Ratio Highlights Mar - GuruFocus
Alumis Inc. (ALMS) reports $235M loss but ends quarter with $502M cash - Stock Titan
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements - The Manila Times
Earnings Flash (ALMS) Alumis Inc. Reports Q2 Revenue $1.7M, vs. FactSet Est of $3.5M - marketscreener.com
Earnings Flash (ALMS) Alumis Inc. Reports Q2 Revenue $1.7M, Vs. FactSet Est of $3.5M - Moomoo
California State Teachers Retirement System Raises Stock Position in Alumis Inc. $ALMS - MarketBeat
Alumis Inc. (ALMS) Climbs 1.69% as Biotech Stock Approaches Key Resistance at $27.09Value Area High - vinanet.vn
Alumis (NASDAQ:ALMS) Trading Down 9.6%Should You Sell? - MarketBeat
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026 - The Globe and Mail
Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates - Benzinga
Alumis reports 54% complete skin clearance in psoriasis trial By Investing.com - Investing.com South Africa
Alumis reports 54% complete skin clearance in psoriasis trial - Investing.com
Alumis: Envudeucitinib Shows 54% PASI 100 at 48 Weeks, NDA on Track for 4Q 2026 - TradingView
First Trust Advisors LP Takes $1.46 Million Position in Alumis Inc. $ALMS - MarketBeat
Alumis Inc (ALMS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alumis Inc. $ALMS Shares Bought by The Manufacturers Life Insurance Company - MarketBeat
Technical Reactions to ALMS Trends in Macro Strategies - Stock Traders Daily
FMR reports 5.5% Alumis Inc (ALMS) stake in Schedule 13G filing - stocktitan.net
Bank of New York Mellon Corp Raises Holdings in Alumis Inc. $ALMS - MarketBeat
Alumis (NASDAQ:ALMS) Insider Jorn Drappa Sells 2,447 Shares of Stock - MarketBeat
Alumis (NASDAQ:ALMS) Insider Sanam Pangali Sells 1,364 Shares of Stock - MarketBeat
Alumis (NASDAQ:ALMS) CFO John Schroer Sells 3,282 Shares - MarketBeat
Alumis (ALMS) CFO sells 3,282 shares in tax-related sell-to-cover trade - Stock Titan
Alumis Inc. (ALMS) officer sells 2,692 shares in tax sell-to-cover trade - Stock Titan
Alumis Inc. (ALMS) CDO sells 2,572 shares to cover RSU taxes - stocktitan.net
Alumis (ALMS) to Post Quarterly Earnings on Wednesday - MarketBeat
Alumis (NASDAQ:ALMS) Given Neutral Rating at HC Wainwright - MarketBeat
Alumis (NASDAQ:ALMS) Trading Down 4.1%Should You Sell? - MarketBeat
Janus Henderson Group PLC Takes $46.79 Million Position in Alumis Inc. $ALMS - MarketBeat
Swiss National Bank Takes $2.81 Million Position in Alumis Inc. $ALMS - MarketBeat
Stempoint Capital LP Buys New Stake in Alumis Inc. $ALMS - MarketBeat
166,959 Shares in Alumis Inc. $ALMS Purchased by Ally Bridge Group NY LLC - MarketBeat
Elmind Capital LP Purchases New Shares in Alumis Inc. $ALMS - MarketBeat
BlackRock, Inc. (ALMS) reports 7.1M-share, 5.7% beneficial stake in Alumis - Stock Titan
Alumis Market Sentiment - Benzinga España
ALMS|Alumis Inc|Price:27.070|Chg%:-0.930 - TradingKey
Orbimed Advisors LLC Has $12.08 Million Stock Holdings in Alumis Inc. $ALMS - MarketBeat
ALMS|Alumis Inc|Price:26.312|Chg%:-0.768 - TradingKey
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alumis Inc Stock (ALMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pangali Sanam | Chief Legal Officer |
Aug 03 '26 |
Sale |
26.37 |
1,364 |
35,969 |
9,747 |
| Hardiman Roy C. | Chief Business & Strategy Ofcr |
Aug 03 '26 |
Sale |
26.37 |
2,692 |
70,988 |
207,746 |
| Goldstein David M | Chief Scientific Officer |
Aug 03 '26 |
Sale |
26.37 |
2,596 |
68,457 |
30,970 |
| Drappa Jorn | Chief Medical Officer |
Aug 03 '26 |
Sale |
26.37 |
2,447 |
64,527 |
56,892 |
| Bradley Mark Christopher | Chief Development Officer |
Aug 03 '26 |
Sale |
26.37 |
2,572 |
67,824 |
48,533 |
| Pangali Sanam | Chief Legal Officer |
Jul 06 '26 |
Option Exercise |
5.06 |
5,000 |
25,300 |
16,111 |
| Pangali Sanam | Chief Legal Officer |
Jul 06 '26 |
Sale |
28.00 |
5,000 |
140,000 |
11,111 |
0.86%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):